(Total Views: 538)
Posted On: 03/18/2025 6:09:25 AM
Post# of 154593
Lab_Monkey_
Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): a Randomized, Double-Blind, Placebo-Controlled Trial
This JAIDS article was just posted on the Publications page of the Cytodyn website. As has been stated before, the cadence of the release of information, and the delay of release in relation to the published date is very interesting. They are definitely a step ahead of the public sphere of knowledge.
Conclusions:
Leronlimab resulted in significantly reduced plasma HIV-1 within one week after addition to failing ART. After 24 weeks combined with an OBT, most participants had plasma HIV-1 RNA levels <50 copies per mL plasma, suggesting utility of leronlimab as a component of salvage therapy.
Yang, Otto O. MDd; Lalezari, Jacob P. MDf,g; Sacha, Jonah B. PhDh; Hansen, Scott G. PhDh; Meidling, Joseph MBAg; etal.
Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): a Randomized, Double-Blind, Placebo-Controlled Trial
This JAIDS article was just posted on the Publications page of the Cytodyn website. As has been stated before, the cadence of the release of information, and the delay of release in relation to the published date is very interesting. They are definitely a step ahead of the public sphere of knowledge.
Conclusions:
Leronlimab resulted in significantly reduced plasma HIV-1 within one week after addition to failing ART. After 24 weeks combined with an OBT, most participants had plasma HIV-1 RNA levels <50 copies per mL plasma, suggesting utility of leronlimab as a component of salvage therapy.
Yang, Otto O. MDd; Lalezari, Jacob P. MDf,g; Sacha, Jonah B. PhDh; Hansen, Scott G. PhDh; Meidling, Joseph MBAg; etal.
(7)
(0)
